Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1997 1
2002 2
2003 1
2006 1
2007 1
2008 1
2009 1
2016 1
2018 1
2019 5
2020 7
2021 6
2022 2
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for oving i
Search for Ovign I instead (1 results)
Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
van Ramshorst MS, van der Voort A, van Werkhoven ED, Mandjes IA, Kemper I, Dezentjé VO, Oving IM, Honkoop AH, Tick LW, van de Wouw AJ, Mandigers CM, van Warmerdam LJ, Wesseling J, Vrancken Peeters MT, Linn SC, Sonke GS; Dutch Breast Cancer Research Group (BOOG). van Ramshorst MS, et al. Among authors: oving im. Lancet Oncol. 2018 Dec;19(12):1630-1640. doi: 10.1016/S1470-2045(18)30570-9. Epub 2018 Nov 6. Lancet Oncol. 2018. PMID: 30413379 Clinical Trial.
Sex differences in out-of-hospital cardiac arrest.
Oving I, Blom MT, Tan HL. Oving I, et al. Aging (Albany NY). 2020 Apr 3;12(7):5588-5589. doi: 10.18632/aging.102980. Epub 2020 Apr 3. Aging (Albany NY). 2020. PMID: 32244225 Free PMC article. No abstract available.
Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial.
van der Voort A, van Ramshorst MS, van Werkhoven ED, Mandjes IA, Kemper I, Vulink AJ, Oving IM, Honkoop AH, Tick LW, van de Wouw AJ, Mandigers CM, van Warmerdam LJ, Wesseling J, Vrancken Peeters MT, Linn SC, Sonke GS. van der Voort A, et al. Among authors: oving im. JAMA Oncol. 2021 Jul 1;7(7):978-984. doi: 10.1001/jamaoncol.2021.1371. JAMA Oncol. 2021. PMID: 34014249 Free PMC article. Clinical Trial.
Oligometastatic Prostate Cancer: Results of a Dutch Multidisciplinary Consensus Meeting.
Aluwini SS, Mehra N, Lolkema MP, Oprea-Lager DE, Yakar D, Stoevelaar H, van der Poel H; Dutch Oligometastatic Prostate Cancer Working Group; Busstra M, de Jong IJ, de Reijke T, de Vries K, Heijmink S, Jenster G, Klaver S, Kneppers J, Lavalaye J, Leyten G, Moonen L, Nagaraj J, Noordzij W, Osanto S, Oving I, Schaake E, Scheenen T, Schoots I, Sedelaar M, Somford D, van den Berkmortel F, van der Hulle T, van der Voort van Zyp J, van Leeuwen P, van Moorselaar J, van Oort I, Vogel W, Westgeest H. Aluwini SS, et al. Among authors: oving i. Eur Urol Oncol. 2020 Apr;3(2):231-238. doi: 10.1016/j.euo.2019.07.010. Epub 2019 Aug 8. Eur Urol Oncol. 2020. PMID: 31401014
Molecular causes of colon cancer.
Oving IM, Clevers HC. Oving IM, et al. Eur J Clin Invest. 2002 Jun;32(6):448-57. doi: 10.1046/j.1365-2362.2002.01004.x. Eur J Clin Invest. 2002. PMID: 12059991 Review.
Genetic Aspects and Molecular Testing in Prostate Cancer: A Report from a Dutch Multidisciplinary Consensus Meeting.
Mehra N, Kloots I, Vlaming M, Aluwini S, Dewulf E, Oprea-Lager DE, van der Poel H, Stoevelaar H, Yakar D, Bangma CH, Bekers E, van den Bergh R, Bergman AM, van den Berkmortel F, Boudewijns S, Dinjens WNM, Fütterer J, van der Hulle T, Jenster G, Kroeze LI, van Kruchten M, van Leenders G, van Leeuwen PJ, de Leng WWJ, van Moorselaar RJA, Noordzij W, Oldenburg RA, van Oort IM, Oving I, Schalken JA, Schoots IG, Schuuring E, Smeenk RJ, Vanneste BGL, Vegt E, Vis AN, de Vries K, Willemse PM, Wondergem M, Ausems M. Mehra N, et al. Among authors: oving i. Eur Urol Open Sci. 2023 Jan 25;49:23-31. doi: 10.1016/j.euros.2022.11.011. eCollection 2023 Mar. Eur Urol Open Sci. 2023. PMID: 36874601 Free PMC article.
Early On-treatment Circulating Tumor DNA Measurements and Response to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer.
Tolmeijer SH, van Wilpe S, Geerlings MJ, von Rhein D, Smilde TJ, Kloots ISH, Westdorp H, Coskuntürk M, Oving IM, van Ipenburg JA, van der Heijden AG, Hofste T, Weiss MM, Schalken JA, Gerritsen WR, Ligtenberg MJL, Mehra N. Tolmeijer SH, et al. Among authors: oving im. Eur Urol Oncol. 2024 Apr;7(2):282-291. doi: 10.1016/j.euo.2023.08.009. Epub 2023 Sep 4. Eur Urol Oncol. 2024. PMID: 37673768 Free article.
The Intestinal Wnt/TCF Signature.
Van der Flier LG, Sabates-Bellver J, Oving I, Haegebarth A, De Palo M, Anti M, Van Gijn ME, Suijkerbuijk S, Van de Wetering M, Marra G, Clevers H. Van der Flier LG, et al. Among authors: oving i. Gastroenterology. 2007 Feb;132(2):628-32. doi: 10.1053/j.gastro.2006.08.039. Epub 2006 Aug 18. Gastroenterology. 2007. PMID: 17320548
RNA Biomarkers as a Response Measure for Survival in Patients with Metastatic Castration-Resistant Prostate Cancer.
Boerrigter E, Benoist GE, van Oort IM, Verhaegh GW, de Haan AFJ, van Hooij O, Groen L, Smit F, Oving IM, de Mol P, Smilde TJ, Somford DM, Hamberg P, Dezentjé VO, Mehra N, van Erp NP, Schalken JA. Boerrigter E, et al. Among authors: oving im. Cancers (Basel). 2021 Dec 14;13(24):6279. doi: 10.3390/cancers13246279. Cancers (Basel). 2021. PMID: 34944897 Free PMC article.
31 results